Elsevier

Autoimmunity Reviews

Volume 8, Issue 4, February 2009, Pages 349-353
Autoimmunity Reviews

CD5: A safeguard against autoimmunity and a shield for cancer cells

https://doi.org/10.1016/j.autrev.2008.11.007Get rights and content

Abstract

CD5 is a pan T cell marker also expressed at various developmental and activation stages on human B cells. CD5 is a well established negative regulator of TCR and BCR signalling. In the last years, great advances have been made in understanding the molecular mechanisms behind this regulatory function. Using animal models, it was demonstrated that increased expression of CD5 on either T cells or B cells protects against autoimmunity; as a consequence of an increase of the threshold needed for TCR- or a BCR-mediated activation following antigen recognition. CD5-positive cells may also prevent the emergence of autoimmunity by provision of cytokines such as IL-10. Although the physiological role of CD5 might be to control the generation of aberrant immune responses, the expansion of CD5+ lymphocytes may be deleterious. The other side of the coin is that in cancers, CD5 expression plays a role in the fate of tumour-specific T cells, rendering lymphocytes tolerant and unable to recognize and eliminate malignant cells. IL-10-producing B-cells may also inhibit anti-tumoural immune responses. An important issue is therefore to better understand the molecules produced by tolerogenic or immunogenic microenvironments that respectively turn on or downregulate CD5 expression, with potential therapeutic implications.

Introduction

The CD5 molecule has been discovered 30 years ago [1], [2], and although much knowledge has been gained since then about its signalling functions in lymphocytes [3], [4], [5], this molecule remains an important field of investigations. This is notably due to the demonstration that CD5 participates to the immune regulatory network which control autoimmune processes and protects against autoimmunity. Therefore, understanding both how CD5 expression is regulated in lymphocytes and what is the nature of signals, either intracellular or cytokine-mediated, delivered by this molecule in order to hold harmful lymphocytes at bay is worth investigating.

Section snippets

Expression and regulation of CD5 on lymphocytes

CD5 is a pan-T cell marker the expression of which increases in parallel with that of the CD3/TCR complex during T-cell development in the thymus, reviewed in [5]. CD5 can be expressed on all lymphocytes but NK cells, furthermore, although CD5 is expressed on the earliest thymic progenitors, it is lost in NK-committed progenitors whereas it is present on T- and B-cell-committed progenitors [5]. All peripheral blood T-cells are CD5hi with CD5 expression at least tenfold that observed on normal

CD5 as a negative regulator of TCR and BCR signalling

CD5 was initially described as a costimulator of the TCR engagement, inasmuch as CD5 antibodies can boost TCR-mediated T-cell proliferation [21], [22]. The molecular mechanisms underlying T-cell stimulation are still unclear but may involve an indirect interaction of CD5 with ZAP-70 through the binding to TCR-p21 zeta chain in human thymocytes [23]. Of note also is the fact that CD5 is phosphorylated on tyrosine upon TCR-engagement [24].

By establishing CD5 “KO” mice, Tarakhovsky et al.,

CD5-regulated gene expression

In order to better understand the possible role of CD5 in B-cells, we introduced CD5 into Burkitt-derived CD5-negative, Daudi B-cells and selected the transfected clones for high CD5 expression. CD5-transfected cells responded poorly to stimulation with F(ab)'2 anti-IgM in comparison to control—vector only—transfected, cells [8] as expected from previously published data; However when analysing the production of IL-10, a cytokine produced by normal CD5+ B-cells, we observed that CD5-transfected

Both enhanced expression of CD5 on B-cells, and B-cell produced IL-10 protect from autoimmune diseases

The role of CD5-expressing B-1a cells in autoimmunity has been described in detail [31] especially their propensity to produce high levels of IL-10. This property together with their production of natural IgM endowed with low affinity and polyreactivity for autoantigens, suggest that B-1a cells protect from autoimmunity likely by removing autoantigens and apoptotic cells [32]. In addition, the specific role of CD5 and IL-10 in the protection from autoimmunity has been demonstrated in vivo.

  • 1)

    The

Upregulation of CD5 on T-cells protects fromautoimmunity in EAE

1) EAE is a good model of human multiple sclerosis; this disease can be induced in mice upon injection of myelin oligodendrocyte glycoprotein (MOG) and Freund's complete adjuvant. In an elegant study, Nussenzweig's group prevented the disease by injecting mice with tolerogenic dendritic cells, (DC) [36]. To achieve this, the authors used a hybrid Ab capable to target simultaneously MOG and DEC-205, an endocytic receptor highly expressed by DC. This receptor carried MOG into the

The role of B-cells and tumour-infiltrating T-lymphocytes (TIL) in the immune response to tumours

  • 1)

    B-cell depletion can enhance immune responses to some tumours [34]. This was demonstrated by injection of wild type or B-cell-deficient mice with various tumours. Whereas wild type mice are unable to control tumour growth, B-cell-deficient animals elicit tumour-specific T-cell immunity characterized by the production of IFN-gamma. This production is inhibited by B-cells or by rIL-10. Thus B lymphocytes are detrimental to anti-tumour immunity, however B-cells seldom infiltrate solid tumours.

Conclusions and perspectives

A number of human and animal studies indicate that in certain conditions, autoantigens, antigen-presenting cells APC, cytokines or stromal cells from tumours regulate the expression of CD5 on T- and B-cells. CD5 is upregulated on “tolerogenic” lymphocytes from either the T or the B-lineage the latter being regulatory B-cells [34]. This avoids uncontrolled over reactivity to self antigens but may be harmful in cancers as it inhibits the killing of malignant cells by the immune system. Although a

Take-home messages

  • CD5 prevents T- and B-lymphocytes from uncontrolled self reactivity.

  • CD5 inhibits TCR and BCR early signalling events; CD5-positive B-cells, protect from autoimmunity by production of cytokines such as IL-10.

  • The “tolerogenic” effect of CD5 prevents tumour-infiltrating lymphocytes from lysing malignant cells.

  • Inducing CD5 expression on lymphocytes may be protective in autoimmune diseases, conversely, inhibiting CD5 expression on tumour-infiltrating-lymphocytes may help CD8+ T-cells to kill

Acknowledgements

Fathia Mami-Chouaib and Marie-Christine Béné are acknowledged for helpful comments.

References (40)

  • G. Bikah et al.

    CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells

    Science

    (1996)
  • G. Bismuth et al.

    Signaling functions of the CD5 molecule

    Curr Trends Immunol

    (1998)
  • R. Carsetti et al.

    Peripheral development of B cells in mouse and man

    Immunol Rev

    (2004)
  • J.H. Antin et al.

    B lymphocyte reconstitution after human bone marrow transplantation. Leu1 defines a distinct population of B lymphocytes

    J Clin Invest

    (1987)
  • H.H. Wortis et al.

    B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes

    Proc Natl Acad Sci USA

    (1995)
  • A. Gagro et al.

    CD5-positive and CD5-negative human B-cells converge to an indistinguishable population on signalling through B-cell receptors and CD40

    Immunology

    (2000)
  • K. Morikawa et al.

    Induction of CD5 antigen on human CD5-B cells by stimulation with staphylococcus Aureus Cowan strain

    Int Immunol

    (1993)
  • C.C. Goodnow

    Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires

    Proc Natl Acad Sci USA

    (1996)
  • T. Defrance et al.

    Human interleukin 4 down-regulates the surface expression of CD5 on normal and leukemic B cells

    Eur J Immunol

    (1989)
  • A.S. Freedman et al.

    Expression and regulation of CD5 on in vitro activated human B cells

    Eur J Immunol

    (1989)
  • Cited by (93)

    • Daytime melatonin levels in saliva are associated with inflammatory markers and anxiety disorders

      2020, Psychoneuroendocrinology
      Citation Excerpt :

      The CD5 receptor is an important regulator of lymphocyte selection and immune tolerance (Raman, 2002). Increased expression of CD5 on either T cells or B cells seems to protect against autoimmunity (Dalloul, 2009) and experimental studies have shown better survival in sepsis models when soluble CD5 has been injected into recipient rats (Sarrias et al., 2007; Vera et al., 2009). Elevated levels of soluble CD5 are linked to aging (Paltsev et al., 2016), sepsis (Aibar et al., 2015) and primary Sjögren's syndrome (Ramos-Casals et al., 2001).

    View all citing articles on Scopus
    View full text